{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:56:51Z","timestamp":1787061411715,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T15:19:09Z","timestamp":1670858349000},"page":"606-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced passive safety surveillance of Influvac\u00ae and Influvac\u00ae Tetra: Results from seven consecutive seasons"],"prefix":"10.1016","volume":"41","author":[{"given":"Melanie","family":"Moeller-Arendt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"van de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Nauta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanka","family":"de Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Rogoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nisslein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.001_b0005","unstructured":"European Programme of Work. World Health Organization. 2022. Home (who.int). Accessed on 05 May 2022."},{"key":"10.1016\/j.vaccine.2022.12.001_b0010","unstructured":"Season Influenza Vaccines: An overview for decision-makers. World Health Organization. 2020. 9789240010154-eng.pdf (who.int). Accessed on 05 March 2022."},{"key":"10.1016\/j.vaccine.2022.12.001_b0015","unstructured":"Vaccines against influenza WHO position paper \u2013 November 2012. Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76. English, French. PMID: 23210147."},{"key":"10.1016\/j.vaccine.2022.12.001_b0020","unstructured":"Recommendations on Influenza Vaccination During the 2019\u20132020 Winter Season. World Health Organization. 2019. Influenza-vaccine-recommendations-2019-2020_en.pdf (who.int). Accessed on 05 March 2022."},{"key":"10.1016\/j.vaccine.2022.12.001_b0025","article-title":"Vaccines Europe influenza working group. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate","author":"Preaud","year":"201414813","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2022.12.001_b0030","unstructured":"European Programme of Work: United Action for Better Health.2022. Home (who.int). Accessed on 05 May 2022."},{"key":"10.1016\/j.vaccine.2022.12.001_b0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.trivac.2012.10.001","article-title":"Trivalent inactivated subunit influenza vaccine Influvac\u00ae: 30-year experience of safety and immunogenicity","volume":"1","author":"Van de Witte","year":"2012","journal-title":"Trials in Vaccinology."},{"issue":"40","key":"10.1016\/j.vaccine.2022.12.001_b0040","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1016\/j.vaccine.2018.04.043","article-title":"A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses","volume":"36","author":"van de Witte","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.001_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2019.12.010","article-title":"Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study","volume":"92","author":"Vesikari","year":"2020","journal-title":"Int J Infect Dis."},{"issue":"18","key":"10.1016\/j.vaccine.2022.12.001_b0050","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1016\/j.vaccine.2022.02.088","article-title":"Efficacy and safety of a quadrivalent influenza vaccine in children aged 6\u201335 months: A global, multiseasonal, controlled, randomized Phase III study","volume":"40","author":"Esposito","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.001_b0055","doi-asserted-by":"crossref","unstructured":"Basu I, Agarwal M, Shah V, Shukla V, Naik S, Supe PD, et al. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-10. doi: 10.1080\/21645515.2021.1885278. Epub 2021 May 6. PMID: 33957854; PMCID: PMC8920161.","DOI":"10.1080\/21645515.2021.1885278"},{"key":"10.1016\/j.vaccine.2022.12.001_b0060","unstructured":"Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. European Medicines Agency. 2014. Interim guidance on Enhanced safety surveillance for seasonal flu vaccines post consultation-- PRAC adopted (europa.eu). Accessed on 05 May 2022."},{"key":"10.1016\/j.vaccine.2022.12.001_b0065","unstructured":"Influvac sub-unit Tetra. SmPC. 2021. Influvac sub-unit Tetra - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk). Accessed on 20 June 2022."},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.001_b0070","doi-asserted-by":"crossref","first-page":"e12016","DOI":"10.2196\/12016","article-title":"Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015\u201316: Feasibility Study","volume":"5","author":"de Lusignan","year":"2019","journal-title":"JMIR Public Health Surveill."},{"issue":"8","key":"10.1016\/j.vaccine.2022.12.001_b0075","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s12325-018-0747-4","article-title":"Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis","volume":"35","author":"de Lusignan","year":"2018","journal-title":"Adv Ther."},{"issue":"5","key":"10.1016\/j.vaccine.2022.12.001_b0080","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/21645515.2019.1565258","article-title":"Enhanced passive surveillance of influenza vaccination in England, 2016\u20132017- an observational study using an adverse events reporting card","volume":"15","author":"de Lusignan","year":"2019","journal-title":"Hum Vaccin Immunother."},{"issue":"8","key":"10.1016\/j.vaccine.2022.12.001_b0085","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1080\/21645515.2019.1705112","article-title":"Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017\/2018 season","volume":"16","author":"de Lusignan","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.001_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40264-019-00893-4","article-title":"Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018\/2019 Season","volume":"43","author":"Dos Santos","year":"2020","journal-title":"Drug Saf."},{"issue":"12","key":"10.1016\/j.vaccine.2022.12.001_b0095","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40264-021-01121-8","article-title":"Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019\/2020 Influenza Season","volume":"44","author":"Salamanca de la Cueva","year":"2021","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.001_b0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40264-015-0384-7","article-title":"Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England","volume":"39","author":"McNaughton","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.vaccine.2022.12.001_b0105","unstructured":"EpidemiologischesBulletin. Robert Koch Institut. Epidemiologisches Bulletin 34\/2014 (rki.de). Accessed on 05 November 2022."},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.001_b0110","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1080\/21645515.2019.1608745","article-title":"Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives","volume":"15","author":"Dos Santos","year":"2019","journal-title":"Hum Vaccin Immunother."},{"issue":"18","key":"10.1016\/j.vaccine.2022.12.001_b0115","doi-asserted-by":"crossref","first-page":"30527","DOI":"10.2807\/1560-7917.ES.2017.22.18.30527","article-title":"Passive enhanced safety surveillance for Vaxigrip and Intanza 15 \u00b5g in the United Kingdom and Finland during the northern hemisphere influenza season 2015\/16","volume":"22","author":"Bricout","year":"2017","journal-title":"Euro Surveill."},{"issue":"2","key":"10.1016\/j.vaccine.2022.12.001_b0120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/21645515.2017.1405882","article-title":"Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 \u03bcg) in two European countries during influenza season 2016\/17 and comparison with 2015\/16 season","volume":"14","author":"Chabanon","year":"2018","journal-title":"Hum Vaccin Immunother."},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.001_b0125","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1080\/21645515.2019.1581538","article-title":"Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017\/18 season","volume":"15","author":"Gandhi-Banga","year":"2019","journal-title":"Hum Vaccin Immunother."},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.001_b0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/21645515.2020.1804247","article-title":"Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018\/2019 season","volume":"17","author":"Serradell","year":"2021","journal-title":"Hum Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.001_b0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12889-021-10378-8","article-title":"Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019\/20 influenza season","volume":"21","author":"Chabanon","year":"2021","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.001_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/irv.12685","article-title":"Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59\u00ae -adjuvanted influenza vaccine in older adults: Results from three consecutive seasons","volume":"14","author":"Panatto","year":"2020","journal-title":"Influenza Other Respir Viruses."},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.001_b0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01586187","article-title":"Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies","volume":"15","author":"Beyer","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:03Z","timestamp":1759404243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22015122"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced passive safety surveillance of Influvac\u00ae and Influvac\u00ae Tetra: Results from seven consecutive seasons","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}